Price movement over the last 24 hours
Abbott Laboratories vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Abbott Laboratories trades at $95.32 (market cap $166.94B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.91. The key difference: Abbott Laboratories pays a 2.63% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals.
| ABT | SJNK | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $25.63 |
52-Week Low | $82.57 | $24.75 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
SJNK trades at $24.97, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a consistent dividend schedule, with recent payouts of $0.14 and $0.15 per share. Recent news highlights institutional accumulation by firms like Berkshire Money Management, though analyst sentiment remains cautious due to high-yield bond market risks.
The outlook for SJNK is clouded by bearish technical indicators and concerns over the sustainability of high-yield bond performance. Risks include interest rate sensitivity and credit spread volatility, but steady dividends and institutional interest offer some support. Investors should weigh income stability against potential capital depreciation in a tightening credit environment.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →